6 search results for: ige
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Shigeharu Fujieda, MD, PhD
Professor in the Division of Otorhinolargngology, Head & Neck Surgery | University of Fukui, Matsuoka, Japan
Potential Biomarkers of Subclinical Control in AD Pathophysiology
Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
IL-4 Contributes to Systemic Type 2 Inflammation in AD
In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.
